Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 36 sources its claims cite were checked for support.
Abstract
BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
Overview
CoChat Summary
TL;DR
In adults with diabetes and no evident cardiovascular disease, low-dose aspirin reduced serious vascular events but increased major bleeding, with absolute benefits largely counterbalanced by bleeding hazards. Aspirin did not reduce gastrointestinal or overall cancer incidence over a mean follow-up of 7.4 years.
Key findings
- Serious vascular events occurred in 658 aspirin-group participants (8.5%) vs. 743 placebo-group participants (9.6%) (rate ratio, 0.88; 95% CI, 0.79 to 0.97; P=0.01).
- Major bleeding occurred in 314 aspirin-group participants (4.1%) vs. 245 placebo-group participants (3.2%) (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), mostly gastrointestinal and other extracranial bleeding.
- No significant between-group difference was found for gastrointestinal tract cancer (157 [2.0%] vs. 158 [2.0%]) or any cancer (897 [11.6%] vs. 887 [11.5%]).
- Absolute effects: 91 patients would need to be treated to avoid a serious vascular event over 7.4 years, and 112 to cause a major bleeding event.
Methods
- Randomized trial of 15,480 adults with diabetes but no evident cardiovascular disease, assigned to aspirin 100 mg daily or matching placebo; factorial assignment also included n-3 fatty acids or placebo.
- Primary efficacy outcome was first serious vascular event (myocardial infarction, stroke or transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage); primary safety outcome was first major bleeding event.
- Intention-to-treat time-to-event analyses used log-rank methods; mean follow-up was 7.4 years, with estimated mean adherence 70% in each group.
Limitations
- Stated: analyses for cancer had limited statistical power to detect hypothesized effects, and longer-term follow-up is planned or being continued.
- Stated: intention-to-treat analyses underestimate the effects of actual aspirin use because adherence was incomplete; secondary and exploratory outcomes were not adjusted for multiple comparisons, so confidence intervals should not be used to infer definitive subgroup or secondary effects.
- Evident from the text: participants were predominantly white (96.5%), had type 2 diabetes (94.1%), were recruited in the United Kingdom, and were well treated with cardioprotective therapies (e.g., 75.6% statin use in the aspirin group), which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 4 Not checked · 53 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report fewer serious vascular events with aspirin in both primary and secondary prevention trials. The Abstract’s Interpretation explicitly describes a reduction in occlusive events, while noting that bleeding risk must be weighed against this benefit in primary prevention. (LLM, conf=0.94)
- Supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. source
The Antiplatelet agents/anticoagulants recommendations (page not provided) recommend aspirin for patients with coronary artery disease and state that it reduces saphenous vein graft closure after bypass surgery. This supports the attributed claim that aspirin reduces occlusive vascular events in the guideline’s secondary-prevention setting; the separate statement about first events in diabetes is not part of the quoted claim. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“On average, however, the approximate 50% higher risk of bleeding with aspirin use than with control counterbalanced much of the benefit in these low-risk patients.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report about a 50% increase in major gastrointestinal and other extracranial bleeding with aspirin in primary-prevention trials (RR 1.54). The Discussion says aspirin’s absolute benefits are much smaller in primary than in secondary prevention and that its benefits and bleeding hazards can be approximately balanced, supporting the claim about low-risk patients. (LLM, conf=0.93)
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Only approximately 4% of participants in those trials had diabetes, and the lower relative risk among them was similar to that observed among participants without diabetes (as was also observed in the context of secondary prevention).”
What the sources say
- Partly supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that, in the primary-prevention trials, the proportional reduction in serious vascular events did not differ significantly by history of diabetes. This supports the main comparison, but the passages do not establish the citing sentence’s approximately 4% figure or its diabetes-specific comparison in secondary prevention. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The 2009 Antithrombotic Trialists' Collaboration meta-analysis involving 95,000 patients in six primary prevention trials showed that assignment to aspirin use led to a 12% (95% confidence interval [CI], 6 to 18) lower risk of serious vascular events than control. 1”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report that aspirin increased major gastrointestinal and other extracranial bleeds in primary prevention trials, with a significant excess of major bleeds also observed in secondary prevention trials. This supports the attributed claim that aspirin increases bleeding risk. (LLM, conf=0.94)
- Partly supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. sourceExperimental — accuracy not yet measured
The Antiplatelet agents/anticoagulants recommendations (page unavailable) state that warfarin used with aspirin and/or clopidogrel is associated with increased bleeding risk. The References also list a study of bleeding complications at different aspirin doses, but the guideline passage does not establish the unqualified claim that aspirin use alone increases bleeding risk. (LLM, conf=0.81)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The benefit of ASA in the ASCEND trial was observed on top of statins (75% of patients) and/or anti-hypertensive (∼60% of patients) drugs.292”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [292]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people > 70 years of age (with or without diabetes), the balance appears to have greater risk than bene fi t (144,146).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, the ASCEND trial found benefit of low-dose aspirin in those in this weight range, which would not validate this suggested hypothesis (179).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people >70 years of age (with or without diabetes), the balance appears to have greater risk than benefit (179,181).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There were no significant differences by sex, weight, or duration of diabetes or other baseline factors, including ASCVD risk score.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Cited by
Items 1,001–1,100 of 1,171
Present Use of Aspirin as an Antithrombotic Agent: Current or Outdated Drug?
Sigal, A., Belcastro, F., Furmento, J., Dossi, D., Cerezo, G. H., Trivi, M., & Costabel, J. P. (2022) · Revista Argentina de Cardiología · doi:10.7775/rac.v90.i4.20533 · Cited by 1
Diabetes und kardiovaskuläre Ereignisse: Ursache, Prävention und Therapie
Darius, H. (2022) · Diabetes aktuell · doi:10.1055/a-1879-9266
An international perspective on low-dose aspirin for the primary prevention of myocardial infarction
Dasa, O., Pepine, C. J., & Pearson, T. A. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.11.036
The Prevalence Of Aspirin Use As A Primary Prevention In Hypertensive Patients In Tikrit City
Ali, B. A., Zaidan, Z. J., & Shnawh, R. M. (2022) · Tikrit Journal of Pharmaceutical Sciences · doi:10.25130/tjphs.2022.16.1.3.19.27
Aspirin for primary prevention of cardiovascular disease in women
Lau, E. S. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002114 · Cited by 1
Couto, V. M., Figueirêdo, C. K. M., Braga, T. R. O., Gabriel, I. D. S., Alencar, M. T., & Silva, M. D. L. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.08
Coelho, J. L., Diniz, B. B., Gabriel, I. D. S., Neta, R. L. D. A., Júnior, I. A. T., & Batista, M. S. N. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.15
Cândido, M. T., de Oliveira, K. G. L. G., Neto, M. I. S., Andrade, B. D. N., Rodrigues, S. C., & da Silva, M. F. A. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.01
Holanda, R. J., Cândido, M. T., Júnior, I. A. T., Silva, M. D. L., Maciel, K. R. D. O., & Gabriel, I. D. S. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.05
Uso do bloqueador alfadrenérgico no tratamento do cálculo ureteral: uma revisão integrativa
Pereira, H. F., Rolim, W. S., dos Santos, A. E. R. T., Seabra, C. A. M., Neta, R. L. D. A., & Lacerda, J. I. D. M. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.20
Silva, S. R. P., Coelho, J. L., Batista, M. S. N., Seabra, C. A. M., Varela, B. R. S., & da Silva, M. F. A. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.16
Síndrome da implantação do cimento ósseo: manifestações clínicas e fatores associados
Alencar, A. S., Macêdo, F. E., Neto, M. I. S., Andrade, B. D. N., Rodrigues, S. C., & Braga, T. R. O. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.11
Relação entre uso prolongado de inibidores da bomba de prótons e demência em idosos
Figueirêdo, C. K. M., Soares, F. R. G., Gabriel, I. D. S., de Quental, O. B., Júnior, I. A. T., & Seabra, C. A. M. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.10
de Lima, N. B., Holanda, R. J., Silva, M. D. L., Coutinho, V. E. A., Rodrigues, S. C., & Gabriel, I. D. S. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.03
Uso de aspirina na prevenção primária no paciente diabético: uma revisão integrativa
Falcão, D. C., de Lima, N. B., Gabriel, I. D. S., Junior, F. C. O., Varela, B. R. S., & da Silva, M. F. A. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.07
Síndrome de Burnout em profissionais da saúde do serviço de urgência e emergência
de Carvalho, A. L. V., Alencar, A. S., Silva, M. D. L., Seabra, C. A. M., de Souza, C. E. A., & de Brito, L. M. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.19
Abordagem ao paciente com via aérea difícil em situação de emergência: uma revisão integrativa
Abreu, W. C. D. A., da Silva, J. C., Sarmento, T. D. A. B., Feitosa, A. D. N. A., de Assis, E. V., & Braga, T. R. O. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.18
Rufino, I. E. M., Abreu, W. C. D. A., Júnior, U. M. D. L., de Quental, O. B., Maciel, K. R. D. O., & Gabriel, I. D. S. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.13
Soares, F. R. G., Dias, M. R., de Carvalho, B. M., de Quental, O. B., do Nascimento, I. M. G., & Braga, K. L. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.02
Rolim, W. S., Falcão, D. C., Seabra, C. A. M., Silva, M. D. L., de Souza, C. E. A., & da Silva, M. F. A. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.09
de Oliveira, K. G. L. G., Couto, V. M., Neto, M. I. S., Feitosa, A. D. N. A., de Souza, C. E. A., & de Oliveira, F. C. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.17
Incidência e prevalência de ansiedade em estudantes de medicina: revisão da literatura
Dias, M. R., de Carvalho, A. L. V., Seabra, C. A. M., Vieira, A. G., do Nascimento, I. M. G., & de Brito, L. M. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.06
Temas transversais em saúde coletiva
Feitosa, A. D. N. A., de Assis, E. V., Braga, K. L., de Brito, L. M., Neta, R. L. D. A., & Sarmento, T. D. A. B. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982 · Cited by 1
Macêdo, F. E., Pereira, H. F., Seabra, C. A. M., de Quental, O. B., Varela, B. R. S., & da Silva, F. A. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.14
da Silva, J. C., Rufino, I. E. M., Braga, T. R. O., de Carvalho, B. M., Santos, R. D. C. P., & Sarmento, T. D. A. B. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.12
Efeitos hipotalâmicos do exercício físico no paciente obeso: uma revisão integrativa
Diniz, B. B., Silva, S. R. P., Gabriel, I. D. S., de Quental, O. B., Santos, R. D. C. P., & da Silva, M. F. A. (2022) · Pimenta Cultural eBooks · doi:10.31560/pimentacultural/2022.94982.04
The Heart in Diabetic Hypertensive Patients
Halabi, A., & Marwick, T. H. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_13 · Cited by 1
Advances on Long-Term Antihypertensive Treatment and Diabetes
Chalmers, J. P., & Wang, N. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_21
Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 1
Murphy, E., Cooney, M. T., & McEvoy, J. W. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-16594-8_1
Fall, M., Grenet, G., Le, H.-H., Kassaï, B., Lega, J., Boussageon, R., Mainbourg, S., Marchant, I., Gafsi, J., Dièye, A. M., et al. (2023) · Therapies · doi:10.1016/j.therap.2023.01.011
WITHDRAWN: Adherence to European guidelines for the use of aspirin in primary health care
Moita, C. F., Marau, G., Corte-Real, S., & Dantas, A. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2023.01.022
RetractedNay, I., Hutchinson, D., Rondina, M. T., Kim, K., Kroencke, R. D., Kirkham, A. J., Trujillo, T. C., Tolley, N. D., & Munger, M. A. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2777
Focus on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Multifactorial Approach
Мохорт, Т. В. (2023) · Рецепт · doi:10.34883/pi.2023.26.1.008
Solomon, T., Tadesse, S., Gelaye, A. T., & Tsehay, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2573298/v1 · Cited by 1
Evaluation of the Appropriateness of Aspirin Therapy in a Veteran Population
Joseph, J., Salama, S., & Choudhury, A. (2023) · Federal Practitioner · doi:10.12788/fp.0353
Rudelle, K., Bignon, M., & Nicot, P. (2023) · Médecine · doi:10.1684/med.2023.843
Zhang, M. L., Liu, Q. P., Gong, C., et al. (2023) · PubMed · doi:10.19723/j.issn.1671-167x.2023.03.014
Adjunct Drug Treatment to Reduce Vascular Disease in People with Diabetes
Jenkins, A. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_29
Kim, J. H., Park, D., Lim, H. S., Kang, M. J., Lee, J. H., Yoon, S. Y., & Kim, H. S. (2023) · Medicine · doi:10.1097/md.0000000000034109
Chun, H. J., Park, S. J., Lim, Y. J., & Song, S. Y. (2023) · Springer eBooks · doi:10.1007/978-981-99-0815-8_32
Cardiovascular comorbidity in patients with abdominal aortic aneurysmal disease
Nicolajsen, C. W. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau539410152
Aspirin use for primary prevention in older adults
Luepker, R. V., Hof, J. V., Eder, M., Finnegan, J. R., Oldenburg, N. C., & Duval, S. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18543 · Cited by 2
Aspirin in Cardiovascular Primary Prevention
Fernández, J. R. D. B. (2023) · ANALES RANM · doi:10.32440/ar.2023.140.02.rev02 · Cited by 2
Agewall, S., Roldán, V., & Marín, F. R. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0027
Antithrombotic strategies in primary cardiovascular prevention
Michelotti, E., Ridker, P. M., & Caterina, R. D. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0014
Patrono, C., & Rocca, B. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780192869227.003.0005
Kellerer, M., & Qiu, H. J. (2023) · Diabetes aktuell · doi:10.1055/a-2183-2739
Bolt, J., Barry, A. R., Inglis, C., Lin, S., & Pan, J. (2023) · Canadian Geriatrics Journal · doi:10.5770/cgj.26.693 · Cited by 1
ICOSAPENT ETHYL AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES (NARRATIVE REVIEW)
Serhiyenko, V. A., Serhiyenko, L., Cherkas, A., & Serhiyenko, A. A. (2023) · Proceedings of the Shevchenko Scientific Society Medical Sciences · doi:10.25040/ntsh2023.02.06
Ischaemic Heart Disease in Diabetes
Lehrke, M., & Marx, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch49
Lin, W., Dong, L., Wen, L., Moonasar, N., Wang, Y., & Zhong, L. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2932_23
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Qiu, H. J., Reimer, P., et al. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01141-1
The cardiometabolic syndrome and vascular disease: pivotal role of insulin
Caldarera, T., Tannenbaum, J., & Shapiro, M. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00015-2
Onur, G., Yıldız, N., Aksoy, H., Fidancı, İ., & Başer, D. A. (2024) · Turkish Journal of Family Medicine & Primary Care · doi:10.21763/tjfmpc.1387318
Application of Data Mining in Pharmaceutical Research
Pan, Z., Zhao, L., Jia, D., Lyu, J., & Cao, S. (2024) · Frontiers research topics · doi:10.3389/978-2-8325-4587-4
Zhang, S., Hu, X., Hou, D., Sun, X., & Sun, D. (2024) · medRxiv · doi:10.1101/2024.03.29.24305070 · Cited by 1
Pleiotropic effects of acetylsalicylic acid
Смирнова, М. Д. (2024) · Russian Medical Inquiry · doi:10.32364/2587-6821-2024-8-1-5
Sun, M., Chen, W., Wu, S., & Zhang, J. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.03.110
Antithrombotische Therapiestrategien in der Atherosklerose
Moser, M., & Westermann, D. (2024) · Kardiologie up2date · doi:10.1055/a-2129-5915
Agreement between mega-trials and smaller trials: a meta-research studyPreprint
Kastrati, L., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Khatami, F., Ahanchi, N. S., Llane, A., Meçani, R., Muka, T., & Ioannidis, J. P. A. (2024) · medRxiv · doi:10.1101/2024.05.09.24307122
Exploring the Intersection of Dementia and Myocardial Infarction: Vascular Perspectives
Goyal, A., Ekelmans, A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000718
Cardiovascular Disease Risk and Risk Reduction Strategies in Diabetes Mellitus
Wilson, D. P., Hamilton, L., & Maki, K. C. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_14
Thrombosis, Hemostasis, and Cardiovascular Outcomes
Belur, A. D., Zheng, S., Raza, M., & Kalra, D. K. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_11 · Cited by 1
Okechukwu, U. C., Abonyi, M. C., & Eze, C. C. (2023) · Nigerian Journal of Medicine · doi:10.4103/njm.njm_103_23
Determinantes Del Descontrol Glucémico En Pacientes Con Diabetes Mellitus Tipo 2
Cortés, J. L. H., & Iturbe, E. A. C. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i3.11616
Kardiovaskuläre Primärprävention: bestehende ASS-Therapie fortführen oder absetzen?
Maibaum, T. (2024) · Zeitschrift für Allgemeinmedizin · doi:10.1007/s44266-024-00260-2
Kim, K., Ko, I., Kim, J., & Kim, D.-K. (2024) · Clinics and Practice · doi:10.3390/clinpract14040113 · Cited by 1
Acetylsalicylic acid in primary prevention: a review
Campanini, M., Rizzi, E., Fleetwood, T., Pinna, G., & Giacomini, G. M. (2024) · Italian Journal of Medicine · doi:10.4081/itjm.2024.1770
Horii, T., Oikawa, Y., Kidowaki, K., Shimada, A., & Mihara, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14284
Gong, B., & Ye, W. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000778
Luque-Esparza, L. E., Delgadillo‐Guzmán, D., Mata-Vidal, R. C., Carranza-Almaguer, D., Aispuro, C. E. C., & Maldonado, I. C. (2024) · Journal of Generic Medicines The Business Journal for the Generic Medicines Sector · doi:10.1177/17411343241286994
Diabetes mellitus und kardiovaskuläre Prävention
Kellerer, M., & Qiu, H. J. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2224-6860
Sammons, E. L., Buck, G. A. N., Bowman, L. J., Stevens, W. M., Hammami, I., Parish, S., Armitage, J., & on behalf of the ASCEND Study Collaborative Group (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03741-x
Lamm, G. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02471-w · Cited by 1
Hong, D., Lee, S. H., Heo, J., Shin, D., Cho, J., Güallar, E., Joh, H. S., Kim, H. K., Ha, J., Choi, K. H., et al. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2024.11.001
(2000) · Time to knit · doi:10.1016/s1155-1941(23)46691-7
(2000) · Time to knit · doi:10.1016/s2211-9698(24)47770-4
(2000) · Time to knit · doi:10.1016/s1166-4568(23)46237-7
Tratamiento antiagregante en la prevención primaria de lesiones coronarias no significativas
Esteban-Chapel, J. A., Franco-Peláez, J. A., & Aceña, A. (2025) · Revista Española de Cardiología · doi:10.1016/j.recesp.2025.01.012
Causally Sound Priors for Binary Experiments
Irons, N. J., & Cinelli, C. L. K. (2025) · Bayesian Analysis · doi:10.1214/25-ba1506 · Cited by 1
Detection and Treatment of Chronic Complications
Soe, K. K., & Gunasekaran, U. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch05
Jordan, R., Linares, J., Shadmand, M., & Valencia, D. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-91790-2.00001-0
Stubblefield, W. B., Sullivan, A. E., Cahill, K. N., Amin, T., Boutaud, O. G., Zagol-Ikapitte, I. A., Su, Y. R., Flaherty, D. K., Matlock, B. K., Berger, J. S., et al. (2025) · JVS-Vascular Insights · doi:10.1016/j.jvsvi.2025.100197
Risk Factors and Treatment of Cardiovascular Disease in Type 2 Diabetes
周, 欣. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151242
Population cessation of aspirin use for the prevention of cardiovascular disease
Roeser, S., Duval, S., Luepker, R. V., Eder, M., Finnegan, J. R., & Hof, J. V. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100941
Aspirin and Clinical Outcomes in Individuals with Incidentally Diagnosed Coronary Artery Stenosis
Jin, I. T., Lee, Y., Choi, E., & Lee, S. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.02.004
Antiplatelet therapy for primary prevention of nonsignificant coronary lesions
Chapel, J. A. E., Peláez, J. A. F., & Aceña, Á. (2025) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2025.01.019
Trimarco, V., Izzo, R., Pacella, D., Varzideh, F., Manzi, M. V., Gallo, P., Giugliano, G., Piccinocchi, R., Esposito, G., Piccinocchi, G., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107688 · Cited by 1
Zhou, J., Wang, M., Li, L., et al. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010330899241203115921
Sammons, E. L., Bowman, L. J., Mafham, M. M., & Armitage, J. (2025) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2025.101474
Aspirin for primary prevention: new scores for old questions?
Rocca, B., & Gaziano, J. M. (2025) · Heart · doi:10.1136/heartjnl-2025-325810
Electronic health records-based research in Cardiology: The time has come for pragmatic trials
Seabra, D., Oliveira, A., & Gavina, C. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2024.12.007
Global research trends and hotspots in aspirin studies (2014–2024): a bibliometric perspective
Sun, N., Jia, B., Wei, R., Lou, T., Li, Z., Nie, X., Wang, X., Yu, W., & Li, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1513318
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Qiu, H. J., Reimer, P., et al. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01323-z
Management of Bleeding in Patients on Antiplatelet Treatment and Its Prevention
Gresele, P., & Paciullo, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-89214-1_12
Lin, B.-X., Zhao, R.-Y., Wu, J.-W., et al. (2025) · The Aging Male · doi:10.1080/13685538.2025.2521815
From the ASPREE investigators: Response to Wittes et al.
McNeil, J. J., Tonkin, A. M., Newman, A. B., Williamson, J. D., Woods, R. L., Chan, A. T., Donnan, G. A., Reid, C. M., Nelson, M. R., Espinoza, S. E., et al. (2025) · Clinical Trials · doi:10.1177/17407745251344560
La aspirina en prevención cardiovascular
Girbes, A. H. (2025) · Actualización en Medicina de Familia · doi:10.55783/amf.210705
Proposal of Platelet Anti-aggregation in Transplant Renal Artery Stenosis
Soto, J. A., Santamaria, E. A. O., Martínez, F. A. V., Pérez, R. E., Avelar‐Garnica, F. J., Astorquizaga, M. A. M., Juárez, A. I. F., Ballesteros, S. H., García, J. F., & Hernández-Rivera, J. C. H. (2025) · Cureus · doi:10.7759/cureus.89265
Aspirin for vascular protection in healthy older adults: have we reached a conclusion?
Flather, M. D., & Stefil, M. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf484
Metadata
- Authors
- The ASCEND Study Collaborative Group
- Affiliations
- MRC Population Health Research Unit (GB)
- Corresponding author
- The ASCEND Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-18
- Volume
- 379
- Issue
- 16
- Pages
- 1529-1539
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899755710
- Cited by
- 1,200
- References
- 23
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 123 · 2023: 117 · 2022: 170 · 2021: 176 · 2020: 193 · 2019: 214 · 2018: 33
- FWCI
- 116.42
- Type
- journal article
- Language
- en
- Open access
- green
- ora.ox.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
- Funders
- Mylan EPD
- Solvay Pharmaceuticals
- Bayer Schering
- British Heart Foundation (SP/03/02, SP/08/010/25939, SP/14/13/31114)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- diabetes mellitus, aspirin, primary prevention, cardiovascular events, major bleeding, gastrointestinal bleeding, intracranial hemorrhage, myocardial infarction, stroke, cancer incidence, benefits and risks, ASCEND trial, occlusive vascular disease, antiplatelet therapy, cardiovascular risk reduction, gastrointestinal cancer, cancer mortality
- MeSH terms
- Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Primary Prevention, Risk Factors, Poisson Distribution, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.